English press releases

Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer or HR Positive, HER2 Negative Breast Cancer

Parallel applications based on TROPION-Lung01 and TROPION-Breast01 phase 3 trial results demonstrating Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan significantly improved progression-free survival versus chemotherapy in...

BenevolentAI: Notice of Preliminary Results

LONDON–(BUSINESS WIRE)– BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, will announce its preliminary...

IFF Announces Grant of Employment Inducement Awards

NEW YORK–(BUSINESS WIRE)– IFF (NYSE: IFF) today announced the grant of employment inducement awards to J. Erik Fyrwald, IFF Chief Executive Officer and member of...

FPT Announces First Acquisition in Japan with Full Ownership of Next Advanced Communications (NAC)

HANOI, Vietnam–(BUSINESS WIRE)– FPT Corporation (FPT) has acquired the IT services company Next Advanced Communications NAC Co., Ltd. (NAC), making it FPT’s first merger &...

IFF Named Top Company in the U.S. for Gender Equality in 2024

Company named #1 in America and #10 globally by Equileap’s Gender Equality Global Report & Ranking NEW YORK–(BUSINESS WIRE)– IFF (NYSE: IFF)—a world leader in...

SES Publishes 2023 Annual Report

LUXEMBOURG–(BUSINESS WIRE)– SES S.A. has today published its 2023 Annual Report, following the announcement of the company’s full year financial results for the 12 months...

Sebia Receives U.S. FDA Clearance for the FLC Kappa & Lambda Assays

Expanding its offering for Multiple Myeloma and AL Amyloidosis Testing LISSES, France–(BUSINESS WIRE)– Sebia, a global specialty diagnostic company providing innovative solutions for screening and...

SES Full Year 2023 Results

Execution against 2023 targets and strengthened financial position with C-band. LUXEMBOURG–(BUSINESS WIRE)– SES S.A. announces financial results for the twelve months ended 31 December 2023....

Galderma Announces Record 2023 Net Sales of Over 4 B USD and Significant Core EBITDA Margin Expansion

ZUG, Switzerland–(BUSINESS WIRE)– Galderma: Delivered against full year guidance for another consecutive year with strong financial performance Galderma achieved net sales of 4.082 B USD,...

Customers Empowered to Participate in the Circular Economy through New Lenovo Offering

PC refurbishment expands Lenovo TruScale DaaS IT optimization benefits with more sustainable options Lenovo Certified Refurbished helps extend device lifecycles and bolster sustainability MORRISVILLE, N.C.–(BUSINESS...

MATI and Mescalero Apache Tribe drive ultra-fast connectivity to remote tribal communities with Adtran Mosaic One

News summary: Service provider received federal funding to enhance digital inclusion with high-quality internet for underserved Native American tribal regions Solution built on Adtran fiber...

Rimini Street Announces Fiscal Fourth Quarter and Annual 2023 Financial and Operating Results

LAS VEGAS–(BUSINESS WIRE)– Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, products, and services, the leading third-party support provider for...

FPT and Siemens Ink MOU, Accelerating Multifaceted Cooperation Globally

HANOI, Vietnam–(BUSINESS WIRE)– Global IT corporation FPT recently signed a Memorandum of Understanding (MoU) with the multinational industrial technology conglomerate Siemens, fostering collaboration and mutually...

1NCE is Now Live With Nationwide IoT in Brazil

1NCE customers now have nationwide access to Brazilian networks for better IoT at disruptive rates. 1NCE customers can use IoT everywhere in the Americas from...

Galderma to Showcase Latest Updates From Its Broad, Innovative and Leading Dermatology Portfolio at the 2024 American Academy of Dermatology Annual Meeting

Galderma will present two late-breaking presentations on clinical trials evaluating the long-term efficacy of the investigational monoclonal antibody nemolizumab in prurigo nodularis and its durability...